Live feed16:15:00·71dPRReleasevia QuantisnowSavara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)ByQuantisnow·Wall Street's wire, on your screen.SVRA· Savara Inc.Health Care
